/Illumina%20Inc%20office%20-by%20Georgejason%20via%20iStock.jpg)
San Diego, California-based Illumina, Inc. (ILMN) is a life sciences company offering sequencing- and array-based solutions for genetic and genomic analysis. With a market cap of $19.2 billion, Illumina operates through Core Illumina and GRAIL segments. It is expected to announce its Q2 earnings after the market closes on Tuesday, August 6.
Ahead of the event, analysts expect Illumina to report a profit of $0.23 per share, down 28.1% from $0.32 per share reported in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates over the past four quarters. Its EPS for the last reported quarter grew 12.5% to $0.09 and exceeded the consensus estimates by 200%.